330574-43-1

Upstream product

• 18962-05-5 4-isopropoxybenzaldehyde 
• 352662-23-8 (R)-2-ethoxycarbonyloxy-5-[4-[(5-methyl-2-phenyl-4-thiazolyl)methoxy]phenyl]pentanamide 
• 6674-22-2 1,8-diazabicyclo[5.4.0]undec-7-ene 
• 159017-89-7 (E)-4-isopropoxycinnamaldehyde 
• 159017-03-5 5-[3-[4-[(5-Methyl-2-phenyl-4-thiazolyl)methoxy]-phenyl]propyl]-2,4-oxazolidinedione 
• 159017-18-2 5-[3-(4-isopropoxy-phenyl)-propyl]-oxazolidine-2,4-dione 
• 159017-88-6 (E)-3-(4-isopropoxyphenyl)-2-propen-1-ol 

Relevant academic research and scientific papers

Neovascularization inhibitors

An angiogenesis inhibitor containing a compound represented by the formula wherein R4 is an optionally substituted hydrocarbon group and the like; Xa is a bond and the like; k is an integer of 1 to 3; Ya is an oxygen atom and the like; ring Ea is a benzene ring optionally having additional substituent(s); p is an integer of 1 to 8; R5 is a hydrogen atom and the like; q is an integer of 0 to 6; r is 0 or 1; R8 is a hydroxy group and the like; and R6 and R7 are hydrogen atoms and the like, or a salt thereof is useful as an agent for the prophylaxis or treatment of tumor and the like.

Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities

Two novel classes of 2,4-thiazolidinediones and 2,4-oxazolidinediones with an ω-(azolylalkoxyphenyl)alkyl substituent at the 5-position were prepared and their antidiabetic effects were evaluated in two genetically obese and diabetic animal models, KKAy mice and Wistar fatty rats. A large number of the 2,4-thia(oxa)zolidinediones showed potent glucose- and lipid-lowering activities. The antidiabetic activities of the 2,4-oxazolidinediones were superior to those of the 2,4-thiazolidinediones. Among the compounds, both enantiomers of 5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3- methoxyphenyl]propyl]-2,4-oxazolidinedione (64), one of the most interesting compounds in terms of activity, were synthesized by using an asymmetric O-acetylation of the corresponding α-hydroxyvalerate (26) with immobilized lipase, followed by cyclization of the oxazolidinedione ring. (R)-(+)-64 showed more potent glucose-lowering activity (effective dose (ED)25 = 0.561 mg/kg/d) than (S)-(-)-64 (ED25 > 1.5 mg/kg/d) or pioglitazone (ED25 = 6 mg/kg/d) in KKAy mice. It also exhibited a 10-fold more potent antidiabetic activity (ED25 = 0.05 mg/kg/d) than pioglitazone (ED25 = 0.5 mg/kg/d) in Wistar fatty rats. The antidiabetic effects of this compound are considered to be due to its potent agonistic activity for peroxisome proliferator-activated receptor γ (EC50 = 8.87 nM).